Gmnec M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The combination offers complementary mechanisms of action, providing effective glycemic control in patients inadequately managed by diet, exercise, or monotherapy. Gmnec M 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances like nausea, vomiting, diarrhea, and hypoglycemia, particularly due to Glimepiride. Regular monitoring of blood glucose levels, renal function, and periodic assessment of vitamin B12 levels is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Gmnec M 2 Tablet PR should be used under medical supervision to optimize diabetes management and minimize potential risks.